Michel Afargan

Company: Starget Pharma

Job title: Head Drug Development

Seminars:

Seizing the Value of Class B GPCRs to Develop Novel Drugs for Endocrine & Metabolic Indications 1:00 pm

With the recent successes of GLP-1 drugs such Ozempic and Wegovy, Class B GPCRs are gaining significant interest as they offer new opportunities to address a wide range of unmet patient needs, including endocrine and metabolic indications. Join this workshop for a deep-dive discussion into the structural and functional understanding of class B GPCRs as…Read more

day: Pre-Conference Workshop Day

GPCR Perspectives & Challenges in the Development of Radioligand Therapies – RLT for Nuclear Oncology 9:30 am

The therapeutic roles of GPCRs in the innovation of RLT for nuclear oncology What are the key focal points in novel RLT developments Why peptides are the most attractive ligands for RLTRead more

day: Conference Day Two